Company Summary: Regenerative Medical Technology Group Inc.

Business Overview

• Primary Focus: The company operates primarily in the regenerative medicine industry, specializing in stem cell therapy as a clinical treatment option.
• History & Acquisition: It was originally a numismatic (coin and currency) business but shifted focus after acquiring Global Stem Cell Group Inc. in August 2021.
• Core Activities:
  • Providing products, solutions, equipment, services, and training to medical professionals for the application of stem cell therapies.
  • Patient procedures are performed at clinics operated by the company, notably in Cancun, Mexico, and planned in Dubai, UAE.
  • Education & Training: Conducts physician training through the International Society for Stem Cell Application (ISSCA), with programs in over 20 countries including the US, Mexico, South America, Southeast Asia, and Europe.
  • Product Development & Distribution: Manufactures and sells regenerative products including:
    • Mesenchymal Stem Cells (MSCs)
    • Exosomes and exosome isolation/purification
    • Peptide-based products (e.g., Cellgenic peptides launched in August 2024)
• Global Operations:
  • Clinics: Launched five clinics in Southeast Asia in 2024; Plans for additional clinics in Indonesia, Puerto Rico, Santiago (Chile), Lisbon (Portugal), and other markets in Mexico, the United States, and beyond.
  • Manufacturing:
    • Proprietary manufacturing in Cancún, Mexico, accredited by Cofepris (Mexican FDA), producing MSCs, exosomes, peptides.
    • Dubai facility planned for 2025 after delays.
    • Considering U.S. manufacturing as regulations evolve.
• Strategic Shift:
  • Transitioned from external partnerships to establishing its own clinical network for standardized treatment and protocols.
  • Incorporates vertical integration from manufacturing to clinic operations.
• Research & Development:
  • Focus on advanced exosome characterization, tissue-specific regeneration, biomarker discovery, and delivery systems.
  • Extensive collaboration with academic and clinical partners.
• Educational Leadership:
  • ISSCA provides physician certifications, advanced courses, and international congresses (next major event planned for Q4 2025).
  • Expanding reach and partnerships in academic institutions.

Financial Summary (2024 Data)

• Revenue: approximately $4.1 million (up 70.44% from 2023’s $2.4 million)
  • Revenue by category:
    • Training: $809,654
    • Product supplies: $1,748,960
    • Equipment: $177,225
    • Patient procedures: $1,371,655
• Net Income/Loss:
  • Loss of approximately $5.56 million in 2024 (improved from $9.81 million loss in 2023)
• Assets: around $3.82 million, increased from $2.88 million in 2023
• Liabilities:
  • Total current liabilities of $28.97 million (over $22.2 million in 2023)
  • Significant outstanding debt including convertible notes, promissory notes, and debt in default totaling over $20 million.
• Cash & Equivalents: approximately $1.17 million
• Employees: Not explicitly specified, but management and staff involved in operations, manufacturing, training, and clinical services.
• Customer Base:
  • Number of shareholders: 148 (as of March 31, 2025)
  • Top ownership: Benito Novas owns approximately 95% of voting stock; other significant investors are Ajene Watson LLC and Digital Asset Monetary Network holding about 8.7% collectively.

Note: The company reported substantial accumulated deficits (~$67.55 million) and ongoing operational losses, with continued reliance on debt financing, and is in debt restructuring talks. The business operates on a global scale with a focus on regenerative medicine products, clinical treatments, and physician training, with a strategic growth plan extending into 2025 and beyond.